Precipio Announces Christina Valauri joins the Board of Directors
January 02, 2024 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is pleased to welcome Christina Valauri to its board of directors effective Jan...
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
December 14, 2023 16:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forward...
Precipio Announces Q3-2023 Shareholder Update Call
November 16, 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at...
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
October 18, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from...
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
October 03, 2023 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives...
Precipio Continues to Sign New HemeScreen™ Customers
September 28, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen...
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
September 25, 2023 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent...
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
September 21, 2023 09:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of...
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
September 13, 2023 09:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its Pathology Division has in August exceeded the monthly breakeven...
Precipio Announces Q2-2023 Shareholder Update Call
August 10, 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM...